CL2015001500A1 - Composicion en suspensión topica de finafloxacina; metodo de preparacion y uso para el tratamiento de una infeccion oftalmica, otica o nasal. - Google Patents

Composicion en suspensión topica de finafloxacina; metodo de preparacion y uso para el tratamiento de una infeccion oftalmica, otica o nasal.

Info

Publication number
CL2015001500A1
CL2015001500A1 CL2015001500A CL2015001500A CL2015001500A1 CL 2015001500 A1 CL2015001500 A1 CL 2015001500A1 CL 2015001500 A CL2015001500 A CL 2015001500A CL 2015001500 A CL2015001500 A CL 2015001500A CL 2015001500 A1 CL2015001500 A1 CL 2015001500A1
Authority
CL
Chile
Prior art keywords
finafloxacin
otic
ophthalmic
preparation
treatment
Prior art date
Application number
CL2015001500A
Other languages
English (en)
Inventor
Brent G Boudreaux
Mark J Bridle
Malay Ghosh
Masood A Chowhan
Laman Alani
Bhagwati P Kabra
Bryan H Huynh
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of CL2015001500A1 publication Critical patent/CL2015001500A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015001500A 2012-12-06 2015-06-03 Composicion en suspensión topica de finafloxacina; metodo de preparacion y uso para el tratamiento de una infeccion oftalmica, otica o nasal. CL2015001500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261734268P 2012-12-06 2012-12-06

Publications (1)

Publication Number Publication Date
CL2015001500A1 true CL2015001500A1 (es) 2015-08-28

Family

ID=50881613

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001500A CL2015001500A1 (es) 2012-12-06 2015-06-03 Composicion en suspensión topica de finafloxacina; metodo de preparacion y uso para el tratamiento de una infeccion oftalmica, otica o nasal.

Country Status (17)

Country Link
US (2) US9504691B2 (es)
EP (1) EP2928475B1 (es)
JP (1) JP5980440B2 (es)
KR (1) KR102175743B1 (es)
CN (2) CN109908081A (es)
AR (1) AR093813A1 (es)
AU (1) AU2013356488B2 (es)
BR (1) BR112015010927B1 (es)
CA (1) CA2888641C (es)
CL (1) CL2015001500A1 (es)
ES (1) ES2784653T3 (es)
MX (1) MX2015007182A (es)
PH (1) PH12015501230A1 (es)
RU (1) RU2693476C2 (es)
UA (1) UA115454C2 (es)
WO (1) WO2014088838A1 (es)
ZA (1) ZA201503102B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
DE102015100068A1 (de) * 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832535B2 (ja) * 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
DE19652239A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6685958B2 (en) 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
PT1294358E (pt) * 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
WO2004087043A2 (en) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Stable ophthalmic formulation containing an antibiotic and a corticosteroid
ATE485343T1 (de) * 2004-06-16 2010-11-15 Colour Ltd Verfahren zur herstellung von beta- kupferphthalocyanin-blaupigmenten und deren verwendung
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101977604A (zh) * 2008-02-15 2011-02-16 爱尔康研究有限公司 眼用氟喹诺酮衍生物
WO2010011942A1 (en) 2008-07-25 2010-01-28 Cox Raleigh L A switch and switch actuator
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
JP2010265261A (ja) * 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
UY32758A (es) * 2009-07-02 2010-10-29 Alcon Res Ltd Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
FR2950353B1 (fr) 2009-09-18 2012-01-13 Commissariat Energie Atomique Procede pour ameliorer les proprietes de resistance au frottement.

Also Published As

Publication number Publication date
ZA201503102B (en) 2016-11-30
BR112015010927B1 (pt) 2022-05-10
BR112015010927A2 (pt) 2017-07-11
CN109908081A (zh) 2019-06-21
JP5980440B2 (ja) 2016-08-31
MX2015007182A (es) 2015-10-12
JP2016500079A (ja) 2016-01-07
KR20150090045A (ko) 2015-08-05
ES2784653T3 (es) 2020-09-29
US20160279137A1 (en) 2016-09-29
EP2928475A1 (en) 2015-10-14
KR102175743B1 (ko) 2020-11-06
EP2928475B1 (en) 2020-03-04
RU2015126799A (ru) 2017-01-13
US20140162990A1 (en) 2014-06-12
PH12015501230A1 (en) 2015-08-17
UA115454C2 (uk) 2017-11-10
US9504691B2 (en) 2016-11-29
AU2013356488A1 (en) 2015-04-23
CA2888641A1 (en) 2014-06-12
RU2693476C2 (ru) 2019-07-03
AU2013356488B2 (en) 2018-04-26
AR093813A1 (es) 2015-06-24
EP2928475A4 (en) 2016-05-11
CA2888641C (en) 2021-02-23
WO2014088838A1 (en) 2014-06-12
CN104869999A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
WO2015014993A3 (en) Anti-infective compounds
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP2978409A4 (en) Ophthalmic composition, method for preparing the same, and use of the same
SG11201504805PA (en) Porcine parvovirus 5a, methods of use and vaccine
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112013017267A2 (pt) formulação de lipossomas, suspensão e composição farmacêutica
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112015005627A2 (pt) composto, composição farmacêutica, uso de composto, método de tratamento e invenção.
EP3019149A4 (en) Ocular composition and kits thereof
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
EP3502141A4 (en) TISSUE FACTOR TARGET ANTIBODIES, PREPARATION METHOD AND USE THEREOF
CL2015001500A1 (es) Composicion en suspensión topica de finafloxacina; metodo de preparacion y uso para el tratamiento de una infeccion oftalmica, otica o nasal.
WO2013138338A3 (en) Methods for treating tissue damage associated with ischemia with apoliporotein d
BR112015006272A2 (pt) ''uso cosmético, composto, composição cosmética e método de tratamento cosmético''
EP3116540A4 (en) Compositions and methods for treating, including preventing, parvovirus infections and related diseases
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
EP3017819A4 (en) Pharmaceutical composition for preventing or treating cognitive impairment or concentration impairment disorders, comprising eclalbasaponin or derivative thereof
BR112015003033A2 (pt) composto, composição farmacêutica e uso do composto